Access the full text.
Sign up today, get DeepDyve free for 14 days.
RxNorm RxCUI Codes for Cancer Therapies
J. Malin, K. Kahn, John Adams, L. Kwan, M. Laouri, P. Ganz (2002)
Validity of cancer registry data for measuring the quality of breast cancer care.Journal of the National Cancer Institute, 94 11
A. Chiang (2016)
Why the Quality Oncology Practice Initiative Matters: It's Not Just About Cost.American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting, 35
52242; e-mail: mary-charlton@uiowa
L. Enewold, H. Parsons, Lirong Zhao, D. Bott, D. Rivera, M. Barrett, B. Virnig, J. Warren (2020)
Updated Overview of the SEER-Medicare Data: Enhanced Content and Applications.Journal of the National Cancer Institute. Monographs, 2020 55
D. Potter, R. Brothers, Andrej Kolacevski, Jacob Koskimaki, A. McNutt, Robert Miller, Jatin Nagda, Anil Nair, W. Rubinstein, A. Stewart, Iris Trieb, G. Komatsoulis (2020)
Development of CancerLinQ, a Health Information Learning Platform From Multiple Electronic Health Record Systems to Support Improved Quality of Care.JCO clinical cancer informatics, 4
(2019)
NQF 1857): HER2 Negative or Undocumented Breast Cancer Patients Spared Treatment With HER2-Targeted Therapies
L. Rizzo, P. Richard, William Moser, B. Waldron, M. Wang, W. William, Davis (2020)
Division of Cancer Control and Population SciencesDefinitions
Xianglin Du, C. Key, L. Dickie, R. Darling, J. Geraci, Dong Zhang (2006)
External Validation of Medicare Claims for Breast Cancer Chemotherapy Compared With Medical Chart ReviewsMedical Care, 44
D. Rivera, Clara Lam, L. Enewold, V. Petkov, Q. Tran, S. Brennan, L. Dickie, T. McNeel, A. Noone, Bradley Ohm, Dolly White, J. Warren, A. Mariotto, L. Penberthy (2020)
Development and Utility of the Observational Research in Oncology Toolbox: Cancer Medications Enquiry Database-Healthcare Common Procedure Coding System (HCPCS).Journal of the National Cancer Institute. Monographs, 2020 55
(2019)
KramerM: HL7 FHIR Implementation Guide: Minimal Common Oncology Data Elements (mCODE) Release 1—USRealm | STU1, 2019
(2019)
Prostate Cancer: Combination Androgen Deprivation Therapy for High Risk or Very High Risk Prostate Cancer
National Cancer Institute SEER Program: SEER*Rx Interactive Antineoplastic Drugs Database
PURPOSETo evaluate the completeness of information for research and quality assessment through a linkage between cancer registry data and electronic health record (EHR) data refined by ASCO's health technology platform CancerLinQ.METHODSA probabilistic data linkage between Iowa Cancer Registry (ICR) and an Iowa oncology clinic through CancerLinQ data was conducted for cases diagnosed between 2009 and 2018. Demographic, cancer, and treatment variables were compared between data sources for the same patients, all of whom were diagnosed with one primary cancer. Treatment data and compliance with quality measures were compared among those with breast or prostate cancer; SEER-Medicare data served as a comparison. Variables captured only in CancerLinQ data (smoking, pain, and height/weight) were evaluated for completeness.RESULTSThere were 6,175 patients whose data were linked between ICR and CancerLinQ data sets. Of those, 4,291 (70%) were diagnosed with one primary cancer and were included in analyses. Demographic variables were comparable between data sets. Proportions of people receiving hormone therapy (30% v 26%, P < .0001) or immunotherapy (22% v 12%, P < .0001) were significantly higher in CancerLinQ data compared with ICR data. ICR data contained more complete TNM stage, human epidermal growth factor receptor 2 testing, and Gleason score information. Compliance with quality measures was generally highest in SEER-Medicare data followed by the combined ICR-CancerLinQ data. CancerLinQ data contained smoking, pain, and height/weight information within one month of diagnosis for 88%, 52%, and 76% of patients, respectively.CONCLUSIONLinking CancerLinQ EHR data with cancer registry data led to more complete data for each source respectively, as registry data provides definitive diagnosis and more complete stage information and laboratory results, whereas EHR data provide more detailed treatment data and additional variables not captured by registries.
JCO: Clinical Cancer Informatics – Wolters Kluwer Health
Published: Apr 28, 2022
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.